Clinical trials: Hematopoietic Stem Cell Mobilization
Reperfused Acute Myocardial Infarction
Trial of Hematopoietic Stem Cells in Acute Myocardial Infarction
The aim of this study is to compare the effectiveness of four different strategies for preventing the ventricular postinfarction remodelling: 1) Conventional treatment for reperfunded extensive acute myocardial infarction, 2)…
- Trial name
- TECAM2 (NCT00984178)
- Testing
- Granulocite Colony Stimulating Factor treatment (G-CSF), Bone marrow mononuclear cells
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- TECAM Group
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01076270
- Testing
- plerixafor, filgrastim, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02
The purpose of this study is to determinate the efficacy and safety of the 3-drug induction treatment (RVD; lenalidomide plus bortezomib plus dexamethasone)followed by randomized autologous stem cell mobilization, autologous stem…
- Trial name
- FMG-MM02 (NCT01790737)
- Testing
- Cyclophosphamide, Filgrastim
- Where
- 12 sites in Finland
- Volunteers
- 80 people
- Sponsor
- Kuopio University Hospital
Chronic Lymphocytic Leukemia, Graft vs Host Disease
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
Diseases such as leukemia, lymphoma, and multiple myeloma fall into the category of blood cancers. Some of these conditions can now be cured by bone marrow transplantation (BMT).
- Conditions
- Chronic Lymphocytic Leukemia, Graft vs Host Disease, Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00001637
- Testing
- Blood cell transplantation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Multiple Myeloma
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.
- Trial name
- GENESIS (NCT03246529)
- Testing
- BL-8040 1.25 mg/kg + G-CSF
- Where
- 18 sites in United States, Germany and 3 more
- Volunteers
- 180 people
- Sponsor
- BioLineRx, Ltd.
Hematologic Neoplasms
National Marrow Donor Program Long-Term Donor Follow-Up
This is an observational study of unstimulated bone marrow (BM) and filgrastim-mobilized peripheral blood stem cell (PBSC) donors.
- Trial name
- LTDFU (NCT01362179)
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 21,974 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Multiple Myeloma
Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma
Primary Objective: To determine if Multi Myeloma (MM) patients mobilized with granulocyte colony-stimulating factor (G-CSF) plus plerixafor 240 μg/kg are more likely to achieve a target number of greater than or equal to 6 x 10^6…
- Trial name
- NCT02221479
- Testing
- plerixafor GZ316455, Filgrastim
- Where
- 5 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Genzyme, a Sanofi Company
Poor Ovarian Response, Ovarian Reactivation
Proteomic and Biological Characterisation of Plasma for the Study of Changes Following Ovarian Reactivation Treatment
The samples used in PRGF treatments owe their effectiveness to the handling, concentration, and preservation of their components, which explains why samples obtained with different platelet-rich plasma preparation systems may…
- Trial name
- NCT07376460
- Testing
- Platelet Rich Plasma + BMDSCs mobilization
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Instituto Valenciano de Infertilidad, IVI Alicante
Children Cancer, Solid Tumor
Mobilization by Plerixafor of Haematopoietic Stem Cells in Children
This is a prospective Phase II, monocentre study.
- Trial name
- MEP1 (NCT01225419)
- Testing
- Plerixafor, mozobil
- Where
- France
- Volunteers
- 5 people
- Sponsor
- University Hospital, Clermont-Ferrand
Autologous Haematopoietic Stem Cell Transplant
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients
This is a single-group treatment, phase IV, open label study to assess the mobilization efficacy and safety of plerixafor in combination with G- CSF in male and female participants from 18 to 75 years of age with multiple myeloma…
- Trial name
- NCT05087212
- Testing
- plerixafor + G-CSF
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Sanofi
Plasma Cell Myeloma, Multiple Myeloma
Collection of Transplant Stem Cells for Plasma Cell Myeloma
Background: One beneficial treatment for plasma cell myeloma is high-dose chemotherapy followed by stem cell transplant. Researchers want to collect stem cells from the blood for later transplant.
- Trial name
- NCT01547806
- Testing
- Filgrastim, Plerixafor, Apheresis
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Poor Graft Function, Stem Cell Transplantation
G-CSF Moblized Peripheral Harvest for Poor Engraftment After Stem Cell Transplantation
Poor graft function (PGF) is a common complication after allogeneic stem cell transplantation, which was associated with high mortality. The pathogenesis fo PGF was poorly understood.
- Conditions
- Poor Graft Function, Stem Cell Transplantation, Graft Versus Host Disease
- Trial name
- NCT01857336
- Testing
- infusion of G-CSF mobilized peripheral harvest
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00005631
- Testing
- filgrastim, rituximab, carboplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Healthy
Oxidative Stress as an Acute Exercise-induced Mechanism of Stem and Progenitor Cell Mobilization
It is already known from literature that exercise mobilizes stem and progenitor cells into the peripheral blood. However, the exact mechanisms thereof remain to be fully elucidated.
- Trial name
- EISMO (NCT03747913)
- Testing
- Antioxidative supplementation
- Where
- Switzerland
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Swiss Federal Institute of Technology
Peripheral Blood Stem Cell Transplantation
KRN125 for Mobilization of Hematopoietic Stem Cells
Data collection to evaluate safety and effect of hematopoietic stem cell mobilization into the peripheral blood after a single subcutaneous (SC) dose of KRN125(Pegfilgrastim)in healthy adults.
- Trial name
- NCT03993639
- Testing
- Pegfilgrastim
- Where
- Japan
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Chronic Granulomatous Disease X-linked (X-CGD)
Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD
This is a phase II exploratory study conducted to evaluate the safety and efficacy of the combination of Ibuprofen, G-CSF and Plerixafor as stem cell mobilization regimen in patients affected by X-CGD.
- Trial name
- XCGD-MOBI (NCT03055247)
- Testing
- Ibuprofen, Myelostim, Mozobil
- Where
- 2 sites in Italy
- Volunteers
- 3 people
- Sponsor
- IRCCS San Raffaele
Beta Thalassemia Major, Congenital Anemias
Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major
Betathalassemia major is a disease of the blood and bone marrow. You were born with it and it has made you unable to make normal hemoglobin and red cells. You have been receiving red blood cell transfusions all your life.
- Trial name
- NCT00658385
- Testing
- GCSF, Central venous line placement, Stem cell Collection (leukapheresis)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma
A single center, non-inferiority, two-way cohort clinical study to evaluate the efficacy and safety of pegylated recombinant human granulocyte stimulating factor injection in the mobilization of autologous hematopoietic stem…
- Trial name
- NCT05834751
- Testing
- PEG-rhG-CSF, RhG-CSF
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Ou Bai, MD/PHD
Coronary Artery Disease
Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD)
Aim of the study is to show additional effects of the combined therapy of niacin and statins analyzing number and function of EPCs and other stem cell populations and adiponectin as well as hsCRP levels in patients with CAD.
- Trial name
- NCT00431145
- Testing
- Niacin, Niacin+Statin
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Multiple Myeloma
Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation
This study will examine whether 240 µg/kg plerixafor given alone for up to 4 days is safe and well tolerated in multiple myeloma (MM) patients.
- Trial name
- NCT00396383
- Testing
- plerixafor
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Genzyme, a Sanofi Company